Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC partners with life science companies globally, focusing on innovation in pharmaceuticals, biotechnology, medical devices, diagnostics, and life science tools to address unmet medical needs. The firm invests across four primary opportunity types: inflection capital, growth capital, fallen angels, and larger private equity collaborations/new company formation.
Investment Strategy
Targets investments in biopharmaceutical, medical device, diagnostic, and life science tool companies. Focuses on inflection points, growth stages, turnaround ('fallen angel') opportunities, and collaborative or co-creation private equity deals.
Latest 13F Filing Activity
Bain Capital Life Sciences Investors, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 22 equity positions with a total 13F market value of $799M. The fund increased holdings in Cidara Therapeutics Inc., Upstream Bio Inc., Cabaletta Bio Inc. among other positions. Bain Capital Life Sciences Investors, LLC reduced exposure to Newamsterdam Pharma Company, Disc Medicine Inc., Savara Inc. among others.
Top Holdings
Equity Positions (22)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
N NAMS | NEWAMSTERDAM PHARMA COMPANY | 24.29% | $194.1M | 10,719,110 | $11.44 | $18.11 | -$25.3M |
C CDTX | CIDARA THERAPEUTICS INC | 15.24% | $121.8M | 2,500,680 | $38.04 | $48.71 | +$106.7M |
N NUVL | NUVALENT INC | 13.82% | $110.4M | 1,447,267 | $22.85 | $76.30 | +$7.8M |
P PHVS | PHARVARIS N V | 7.27% | $58.1M | 3,303,381 | $23.53 | $17.60 | +$6.3M |
D DNTH | DIANTHUS THERAPEUTICS INC | 5.79% | $46.2M | 2,482,250 | $29.71 | $18.63 | -$2.5M |